PYPD News and Press, PolyPid Ltd. From 04/25/22

Presentation evaluates the effect of D-PLEX 100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients PETACH TIKVA, Israel, April 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “...

PolyPid develops a platform technology to provide locally controlled and continuous delivery of medications. Lead product candidate D-PLEX100 is investigated for the prevention of sternal and abdominal surgical site infections serving a huge market. Meaningful interim results and ...

Referring to the most up-to-date market data as of Apr. 11, Cantor Fitzgerald has listed the biotech companies with the most notable changes in the short interest. The nano-cap commercial-stage pharma company, Clarus Therapeutics (CRXT) dominates the list with over ten times increase in short...

PETACH TIKVA, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the upco...

PolyPid (NASDAQ:PYPD) entered into a secured loan agreement for up to $15M with Kreos Capital VI. Loan proceeds will be used to support global commercialization preparations for the launch of D-PLEX for the prevention of abdominal soft tissue surgical site infections, as well as fur...

PETACH TIKVA, Israel, April 06, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company has entered into a secured loan agreem...

Presentation Evaluates Efficacy of D-PLEX 100 in Reducing Surgical Site Infection Rates in Elective Colorectal Surgery PETACH TIKVA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company ...

PETACH TIKVA, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary P...

PETACH TIKVA, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its pr...

PolyPid Ltd. (PYPD) Q4 2021 Earnings Conference Call February 9, 2022, 08:30 AM ET Company Participants Bob Yedid - Investor Relations Amir Weisberg - Chief Executive Officer Dikla Czaczkes Akselbrad – Executive Vice President and Chief Financial Officer Conference Call Participants Ha...